Clinical Trials Logo

Ischemic Heart Disease clinical trials

View clinical trials related to Ischemic Heart Disease.

Filter by:

NCT ID: NCT03466151 Active, not recruiting - Clinical trials for Coronary Artery Disease

RESOLUTE ONYX China RCT Study

Start date: April 12, 2018
Phase: N/A
Study type: Interventional

It is a randomized controlled trial to evaluate the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in comparison with the Medtronic Resolute Integrity™ Zotarolimus-Eluting coronary stent system in the treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) in China.

NCT ID: NCT03446313 Completed - Clinical trials for Cardiovascular Diseases

Technology-Based Intervention to Promote Heart Health After Cardiac Rehab (Mobile4Heart)

Mobile4Heart
Start date: February 28, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether using a mobile app increases adherence to a heart healthy prescription after discharge from a cardiac rehab program.

NCT ID: NCT03438500 Withdrawn - Clinical trials for Coronary Artery Disease

Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the epicardial coronary arteries.

NCT ID: NCT03411369 Completed - Clinical trials for Ischemic Heart Disease

Creatine, D-Ribose, B1 Vitamin, and B6 Vitamin in Ischemic Heart Disease

Start date: June 1, 2016
Phase: N/A
Study type: Interventional

Recently, researchers have paid attention to the development of new products such as supplements food and nutraceuticals for identify and develop integrative therapies to be used in cardiovascular disease. As suggested by literature, some nutritional components (creatine, ribose) can enhance the fundamental energy levels for the functioning of the heart muscle and can enhance the body's antioxidant capacity through the reduction in free radicals activity, one of the main pathogenic mechanisms of these diseases. In this context, the investigators have developed a research with the principal purpose to establish whether a supplement of creatine and ribose can improve the total work capacity during exercise in a population of patients with known ischemic heart disease.

NCT ID: NCT03409731 Completed - Clinical trials for Coronary Artery Disease

Absorb GT1 Japan PMS

Start date: December 13, 2016
Phase: N/A
Study type: Interventional

The purpose of the Surveillance is to know the frequency and status of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect efficacy and safety information for evaluating clinical use results.

NCT ID: NCT03404024 Recruiting - Clinical trials for Acute Myocardial Infarction

Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea

Start date: January 25, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical efficacy of VM202RY injected via transendocardial route using C-Cathez® catheter (Celyad, S.A., Belgium) in subjects with AMI. - Stage 1: Evaluation of safety and tolerability of VM202RY injection - Stage 2: Evaluation of safety and efficacy of VM202RY injection

NCT ID: NCT03401216 Recruiting - Clinical trials for Coronary Artery Disease

StEnt Coverage and Neointimal Tissue Characterization After eXtra Long evErolimus - Eluting Stent imPlantation

Start date: March 20, 2017
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the rate of SYNERGY 48 mm stent strut coverage and assess neointimal progression via OCT measurement in patients who underwent PCI.

NCT ID: NCT03397095 Recruiting - Clinical trials for Ischemic Heart Disease

Sequential Treatment of Extra-Corporeal Shock Wave Combined With aUtologous Bone marRow Mesenchymal Stem Cells on Patients With ischEmic Heart Disease : the S-CURE Study

S-CURE
Start date: April 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy, safety and tolerability of autologous bone marrow derived mesenchymal stem cells compared to placebo (sham operation) when administered via percutaneous coronary infusion to patients with ischemic heart disease, who are screened by D-SPECT and have pretreated with 3-month cardiac shock wave therapy.

NCT ID: NCT03391622 Completed - Clinical trials for Ischemic Heart Disease

Thrombin Generation Values and Percutaneous Coronary Intervention Results.

Start date: April 1, 2018
Phase:
Study type: Observational

Cardiovascular diseases are the most common cause of death in the western world. Myocardial infarction pathogenesis usually involves the development of an atherosclerotic plaque and thrombus. Past research has shown a correlation between thrombin generation values and ischemic heart disease, however, to our knowledge no investigation has been done into the correlation of thrombin generation and cardiac catheterization results in ischemic heart disease patients. In the current research the investigator will investigate the correlation of thrombin generation values using calibrated automated thrombogram and cardiac catheterization results in active ischemic heart disease patients.

NCT ID: NCT03383718 Completed - Clinical trials for Ischemic Heart Disease

DSE vs. FFR in SCAD and BYSTANDER Lesions

DSE-vs-FFR
Start date: December 1, 2014
Phase:
Study type: Observational

Enrollment: - Patients with stable coronary artery disease (SCAD) and moderate coronary artery stenoses (30-70 %) - Patients with acute myocardial infarction and moderate stenosis of non-culprit arteries (NCL; BYSTANDER LESION) Aims: - To assess the diagnostic accuracy of dobutamine stress echocardiography (DSE) and invasive fractional flow reserve (FFR) measurement - To assess the prognostic impact of reclassification by a mismatching negative test Hypothesis: - DSE and FFR have similar prognostic value in both clinical settings (SCAD and NCL) - Considering the strong negative predictive value of both DSE and FFR, one negative test is sufficiently enough to defer revascularisation, even in the case of mismatch